Health care startups that raised Series B in China
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Huasaiboman Medical Cell Biology | Qingdao Shi | Series B | $30.0M | 2026-11-09 |
| Enjosim | Shanghai | Series B | $30.1M | 2026-11-02 |
| Hyperway Pharm | Chengdu | Series B | $14.9M | 2026-10-15 |
| Bluesail Surgical | Shanghai | Series B | $104.5M | 2026-09-23 |
| Medefa | Zhuhai | Series B | $14.9M | 2026-09-02 |
| Yuce Biotechnology | Suzhou | Series B | $7.4M | 2026-08-31 |
| MileBot Robotics | Shenzhen | Series B | $14.9M | 2026-08-26 |
| Leadinno Medical Valley | Beijing | Series B | $29.7M | 2026-08-17 |
8 rows of the CSV in 5 of its 18 columns.
- The 664 health care startups in China whose last round is Series B have raised $16.6B in total.
- 106 of them closed their most recent round in the last 12 months, $1.8B combined.
- The largest of those rounds is D3 Bio's $108.0M Series B, dated December 2025.
- The most recent is Huasaiboman Medical Cell Biology's $30.0M Series B on 9 November 2026.
- Qiming Venture Partners is an investor in 14 of them, more than any other fund.
- Biotech is the most common other sector, with 261 companies (39%).
- 12% were founded in 2020 or later; the median founding year is 2015.
- The most common team size is 11 to 50 employees (29% of companies with a recorded size).
- 1 is a unicorn, valued at $1 billion or more.
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
30 of 664| Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Huasaiboman Medical Cell Biology | Huasaiboman Medical Cell Biology provides new cell therapy technologies and solutions as a biotechnology company. | Biotech | Qingdao Shi | Series B | $30.0M | 2026-11-09 | $30.0M | ASBV | 11 to 50 | 2019 |
| Enjosim | Enjosim researches, manufactures, and sells self-delivery systems for biomacromolecule pharmaceuticals. | Biotech | Shanghai | Series B | $30.1M | 2026-11-02 | $30.1M | Luminous Ventures (former Lightspeed China Partners), Jiayuan Capital | 51 to 100 | 2021 |
| Hyperway Pharm | Hyperway Pharm conducts pharmaceutical research, development, and production. | Health care | Chengdu | Series B | $14.9M | 2026-10-15 | $56.8M | Si Chuan Venture Capital, Chengdu High-tech Ceyuan Capital, Huaige Capital +1 | 51 to 100 | 2019 |
| Bluesail Surgical | Bluesail Surgical develops surgical instruments for cardiovascular treatments. | Biotech | Shanghai | Series B | $104.5M | 2026-09-23 | $245.4M | Huagai Capital, Linkong Private Equity Fund Management, Linqu County High-Tech Industrial Investment | 101 to 250 | 2020 |
| Medefa | Medefa uses synthetic biology to mass-produce novel PHA biomaterials. | Biotech | Zhuhai | Series B | $14.9M | 2026-09-02 | $16.3M | Motianshi Touzi, Taiping Innovation | 11 to 50 | 2019 |
| Yuce Biotechnology | Yuce Biotechnology focuses on the industrialization of single-molecule immunodiagnostic technologies. | Biotech | Suzhou | Series B | $7.4M | 2026-08-31 | $22.4M | Puhua Capital, Zhengxuan Investment, BioTrack Capital +2 | 101 to 250 | 2019 |
| MileBot Robotics | MileBot Robotics develops robots for medical and healthcare applications. | Artificial intelligence | Shenzhen | Series B | $14.9M | 2026-08-26 | $14.9M | Lenovo Capital and Incubator Group (LCIG), Share Capital, Shangyuan Capital | 101 to 250 | 2016 |
| Leadinno Medical Valley | Leadinno Medical Valley produces medical devices that regulate neurological functions. | Health care | Beijing | Series B | $29.7M | 2026-08-17 | $90.3M | Fortune Venture Capital, Cowin Capital, Taiyu Investment +2 | 10,001 or more | 2016 |
| Hongxin Biology | Hongxin Biology develops mRNA drugs and delivers nucleic acid therapeutics to patients. | Biotech | Shenzhen | Series B | $14.0M | 2026-08-13 | $14.0M | Haiyuan Capital, Shenzhen Small & Medium Enterprises Credit Financing Guarantee Group | 11 to 50 | 2021 |
| Layerwave Bio | Layerwave Bio develops diagnostic instrument reagents and biomedical research instruments. | Biotech | Daxing | Series B | $13.8M | 2026-07-28 | $13.8M | IDG Capital, Addor Capital, Hotung Venture Capital | 51 to 100 | 2020 |
| MindRank AI | MindRank AI develops artificial intelligence platforms to discover and develop small molecule drugs. | Artificial intelligence | Shanghai | Series B | $52.0M | 2026-07-08 | $101.0M | Green Pine Capital Partners, Huagai Capital, Sherpa Healthcare Partners +1 | 11 to 50 | 2020 |
| Sonosemi Medical | Sonosemi Medical provides medical devices for vascular interventional diagnosis and treatment. | Health care | Shenzhen | Series B | $27.3M | 2026-07-08 | $27.3M | Eight Roads Ventures, Co-Stone Venture Capital, Guangzhou Yuexiu Industrial Investment Fund +1 | 101 to 250 | 2020 |
| X-MAGTECH | X-MAGTECH provides a technology platform for measuring extremely weak magnetic fields. | Health care | Haidian | Series B | $14.8M | 2026-06-04 | $43.5M | IDG Capital, CAS Star, Everest Venture Capital +1 | 101 to 250 | 2018 |
| HemaCell | HemaCell develops cell therapies that regenerate hematopoietic lineages in vitro through stem cell reprogramming. | Biotech | Suzhou | Series B | $14.8M | 2026-06-02 | $62.0M | Northern Light Venture Capital, CDH Investments, CMB International Capital Corporation | 1 to 10 | 2021 |
| Menovex | Menovex develops and markets laser medical devices for treating oral and skin conditions. | Health care | Shenzhen | Series B | $14.8M | 2026-06-02 | $14.8M | Infinity Equity | 2019 | |
| Bivision | Bivision researches and develops targeted radiopharmaceuticals for therapy. | Biotech | Shanghai | Series B | $58.8M | 2026-05-18 | $100.9M | Gaorong Capital, Kaitai Capital, Lichen Capital | 11 to 50 | 2021 |
| Hypershell | Hypershell develops wearable exoskeletons that support walking, hiking, and cycling. | Artificial intelligence | Shenzhen | Series B | $50.0M | 2026-05-18 | $121.2M | MiraclePlus, Decent Capital, Vitalbridge Capital | 101 to 250 | 2021 |
| Novamab | Novamab researches and develops new nanobodies. | Biotech | Shanghai | Series B | $43.9M | 2026-04-24 | $97.8M | Qiming Venture Partners, Taiyu Investment, Fuho Capital +1 | 51 to 100 | 2017 |
| AccuPulse | AccuPulse develops pulsed electric field ablation generators and catheters. | Health care | Suzhou | Series B | $14.5M | 2026-03-13 | $72.5M | BioVenture, Shanghai Biomedical Industrial Equity Investment Fund, Med-Fine Capital +1 | 11 to 50 | 2020 |
| CSR Biotech | CSR Biotech provides cell imaging and data processing services for biological research. | Biotech | Haidian | Series B | $45.0M | 2026-03-10 | $45.0M | Qiming Venture Partners | 51 to 100 | 2019 |
| Tingsheng Technology | Tingsheng Technology develops intracardiac ultrasound (ICE) products. | Health care | Nanjing | Series B | $13.9M | 2026-03-05 | $52.8M | Qiming Venture Partners, Taiyu Investment, Tao Capital +2 | 2017 | |
| RoboCT | RoboCT develops exoskeleton robots that help patients with lower-body motor dysfunction learn to walk. | Artificial intelligence | Yuhang | Series B | $14.5M | 2026-03-04 | $47.3M | Fortune Venture Capital, Poly Capital, Pappas Capital | 51 to 100 | 2017 |
| Findcure | Findcure develops anti-cancer medications through drug discovery and development. | Biotech | Daxing | Series B | $14.5M | 2026-02-14 | $14.5M | Hecheng Capital, Renxi Fund, Yishang Huicheng Investments | 11 to 50 | 2019 |
| Transcend Vivoscope | Transcend Vivoscope is a biotechnology company that offers advanced microscopy imaging products and solutions. | Biotech | Haidian | Series B | $14.5M | 2026-02-10 | $14.5M | China Capital Management, Zefu Innovation, Guangzhou Tongxin Science and Technology Innovation Fund | 11 to 50 | 2016 |
| Alioth | Alioth develops and applies technical products for pharmaceutical process technology. | Biotech | Shanghai | Series B | $14.4M | 2026-01-15 | $54.7M | Matrix Partners China, Legend Capital | 51 to 100 | 2021 |
| Yuewei Medical | Yuewei Medical develops interventional medical devices for cardiac surgery. | Health care | Beijing | Series B | $14.3M | 2026-01-12 | $28.4M | IDG Capital, South China Venture Capital, Yuanhui Chuangyi +1 | 2019 | |
| Anlong Bio | Anlong Bio researches and develops nucleic acid drugs, including gene therapy, RNA drugs, and gene editing. | Biotech | Beijing | Series B | $14.3M | 2026-01-07 | $14.3M | TaiKun Fund | 51 to 100 | 2019 |
| D3 Bio | D3 Bio develops and registers medicines as a biotechnology company. | Biotech | Wuxi Shi | Series B | $108.0M | 2025-12-09 | $370.0M | Matrix Partners China, Boyu Capital, Medicxi | 1 to 10 | 2020 |
| Rigen Biotech | Rigen Biotech provides molecular diagnosis of thyroid tumors. | Biotech | Minhang | Series B | $14.1M | 2025-11-28 | $29.8M | BioTrack Capital, Boyuan Capital, Guotai Junan Innovation Investment +1 | 101 to 250 | 2017 |
| Jingwei Shida | Jingwei Shida researches, develops, and supplies optoelectronic medical equipment. | Health care | Wuhan | Series B | $14.1M | 2025-11-21 | $14.1M | Northern Light Venture Capital, SND Ventures Group, Insight Capital | 11 to 50 | 2014 |
Table 1. Health care startups that raised Series B in China: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 664.
Largest rounds
Last 12 months| # | Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | D3 Bio | D3 Bio develops and registers medicines as a biotechnology company. | Biotech | Wuxi Shi | Series B | $108.0M | 2025-12-09 | $370.0M | Matrix Partners China, Boyu Capital, Medicxi | 1 to 10 | 2020 |
| 2 | Bluesail Surgical | Bluesail Surgical develops surgical instruments for cardiovascular treatments. | Biotech | Shanghai | Series B | $104.5M | 2026-09-23 | $245.4M | Huagai Capital, Linkong Private Equity Fund Management, Linqu County High-Tech Industrial Investment | 101 to 250 | 2020 |
| 3 | Bivision | Bivision researches and develops targeted radiopharmaceuticals for therapy. | Biotech | Shanghai | Series B | $58.8M | 2026-05-18 | $100.9M | Gaorong Capital, Kaitai Capital, Lichen Capital | 11 to 50 | 2021 |
| 4 | MindRank AI | MindRank AI develops artificial intelligence platforms to discover and develop small molecule drugs. | Artificial intelligence | Shanghai | Series B | $52.0M | 2026-07-08 | $101.0M | Green Pine Capital Partners, Huagai Capital, Sherpa Healthcare Partners +1 | 11 to 50 | 2020 |
| 5 | Hypershell | Hypershell develops wearable exoskeletons that support walking, hiking, and cycling. | Artificial intelligence | Shenzhen | Series B | $50.0M | 2026-05-18 | $121.2M | MiraclePlus, Decent Capital, Vitalbridge Capital | 101 to 250 | 2021 |
| 6 | CSR Biotech | CSR Biotech provides cell imaging and data processing services for biological research. | Biotech | Haidian | Series B | $45.0M | 2026-03-10 | $45.0M | Qiming Venture Partners | 51 to 100 | 2019 |
| 7 | Novamab | Novamab researches and develops new nanobodies. | Biotech | Shanghai | Series B | $43.9M | 2026-04-24 | $97.8M | Qiming Venture Partners, Taiyu Investment, Fuho Capital +1 | 51 to 100 | 2017 |
| 8 | Enjosim | Enjosim researches, manufactures, and sells self-delivery systems for biomacromolecule pharmaceuticals. | Biotech | Shanghai | Series B | $30.1M | 2026-11-02 | $30.1M | Luminous Ventures (former Lightspeed China Partners), Jiayuan Capital | 51 to 100 | 2021 |
| 9 | Huasaiboman Medical Cell Biology | Huasaiboman Medical Cell Biology provides new cell therapy technologies and solutions as a biotechnology company. | Biotech | Qingdao Shi | Series B | $30.0M | 2026-11-09 | $30.0M | ASBV | 11 to 50 | 2019 |
| 10 | Leadinno Medical Valley | Leadinno Medical Valley produces medical devices that regulate neurological functions. | Health care | Beijing | Series B | $29.7M | 2026-08-17 | $90.3M | Fortune Venture Capital, Cowin Capital, Taiyu Investment +2 | 10,001 or more | 2016 |
Table 2. Health care startups that raised Series B in China: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Qiming Venture Partners | Venture capital firm | Shanghai, China | 14 | 2% | 3 | Novamab, CSR Biotech, Tingsheng Technology |
| 2 | IDG Capital | Private equity firm | Beijing, China | 11 | 2% | 3 | Layerwave Bio, X-MAGTECH, Yuewei Medical |
| 3 | Matrix Partners China | Venture capital firm | Beijing, China | 9 | 1% | 2 | Alioth, D3 Bio |
| 4 | Legend Capital | Venture capital firm | Beijing, China | 8 | 1% | 1 | Alioth |
| 5 | Puhua Capital | Venture capital firm | Hangzhou, China | 6 | 1% | 1 | Yuce Biotechnology |
| 6 | CDH Investments | Private equity firm | Kowloon City, Hong Kong | 6 | 1% | 1 | HemaCell |
| 7 | Shenzhen Capital Group | Venture capital firm | Nanshan, China | 6 | 1% | ||
| 8 | BioTrack Capital | Venture capital firm | Shanghai, China | 5 | 1% | 2 | Yuce Biotechnology, Rigen Biotech |
| 9 | Lenovo Capital and Incubator Group (LCIG) | Venture capital firm | Beijing, China | 5 | 1% | 1 | MileBot Robotics |
| 10 | Taiyu Investment | Venture capital firm | Beijing, China | 5 | 1% | 3 | Leadinno Medical Valley, Novamab, Tingsheng Technology |
| 11 | Fortune Venture Capital | Venture capital firm | Shenzhen, China | 5 | 1% | 2 | Leadinno Medical Valley, RoboCT |
| 12 | Northern Light Venture Capital | Venture capital firm | Beijing, China | 5 | 1% | 2 | HemaCell, Jingwei Shida |
| 13 | Sinovation Ventures | Venture capital firm | Beijing, China | 5 | 1% | ||
| 14 | Sherpa Healthcare Partners | Venture capital firm | Beijing, China | 4 | 1% | 1 | MindRank AI |
| 15 | Green Pine Capital Partners | Venture capital firm | Shenzhen, China | 4 | 1% | 1 | MindRank AI |
Table 3. Health care startups that raised Series B in China: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Biotech | 261 | 39% | $7.9B |
| Software | 86 | 13% | $1.7B |
| Hardware | 44 | 7% | $500.1M |
| Artificial intelligence | 34 | 5% | $968.0M |
| Commerce | 25 | 4% | $2.0B |
| Education | 12 | 2% | $109.8M |
| Fintech | 7 | 1% | $117.3M |
| Energy | 3 | 0% | |
| Cybersecurity | 1 | 0% |
Table 4. Health care startups that raised Series B in China by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series B | 664 | 100% | $14.4M |
Table 5. Health care startups that raised Series B in China by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Cities
Table 6. Health care startups that raised Series B in China by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 6 | 6% | $90.0M |
| October 2026 | 5 | 5% | $145.3M |
| September 2026 | 8 | 8% | $311.3M |
| August 2026 | 6 | 6% | $80.5M |
| July 2026 | 7 | 7% | $207.2M |
| June 2026 | 7 | 7% | $44.3M |
| May 2026 | 7 | 7% | $179.2M |
| April 2026 | 6 | 6% | $75.6M |
| March 2026 | 12 | 11% | $166.5M |
| February 2026 | 11 | 10% | $85.9M |
| January 2026 | 12 | 11% | $130.1M |
| December 2025 | 13 | 12% | $230.5M |
| November 2025 | 6 | 6% | $42.3M |
Table 7. Health care startups that raised Series B in China: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 87 | 13% | $1.5B |
| 2025 | 77 | 12% | $921.4M |
| 2024 | 52 | 8% | $732.9M |
| 2023 | 67 | 10% | $974.4M |
| 2022 | 66 | 10% | $1.5B |
| 2021 | 56 | 8% | $2.5B |
Table 8. Health care startups that raised Series B in China by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 1 | 0% |
| 2020 to 2022 | 76 | 12% |
| 2015 to 2019 | 288 | 44% |
| 2010 to 2014 | 178 | 27% |
| Before 2010 | 115 | 17% |
Table 9. Health care startups that raised Series B in China by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 62 | 10% |
| 11 to 50 | 174 | 29% |
| 51 to 100 | 131 | 22% |
| 101 to 250 | 120 | 20% |
| 251 to 500 | 60 | 10% |
| 501 to 1,000 | 22 | 4% |
| 1,001 to 5,000 | 19 | 3% |
| 5,001 to 10,000 | 3 | 1% |
| 10,001 or more | 2 | 0% |
Table 10. Health care startups that raised Series B in China by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Health care is one of its sectors and its most recent funding round is Series B and its headquarters is in China. On 16 November 2026 that is 664 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 30 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 664 rows: 202 have no round amount, 0 no city and 196 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many health care startups in China whose last round is Series B are on the list?
- 664, in the file dated 16 November 2026. 106 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 664 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $349.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.